BridgeBio Oncology Therapeutics, Inc. Income Statement
BBOT / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| SG&A Expense | $584.4K | $41.7K |
| Operating Income | -$584.4K | -$41.7K |
| Income Tax | $0 | - |
| Net Income | $7.6M | -$41.7K |